Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of “Hold” by Analysts

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been assigned an average rating of “Hold” from the ten analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $22.2857.

A number of analysts have weighed in on KROS shares. Zacks Research lowered shares of Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Wedbush increased their price target on shares of Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Bank of America boosted their price objective on shares of Keros Therapeutics from $18.00 to $19.00 and gave the stock a “neutral” rating in a report on Friday, November 28th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Keros Therapeutics in a research note on Monday, December 29th. Finally, TD Cowen raised Keros Therapeutics to a “hold” rating in a report on Friday, December 19th.

Keros Therapeutics Trading Down 0.2%

Keros Therapeutics stock opened at $16.58 on Monday. Keros Therapeutics has a 12 month low of $9.12 and a 12 month high of $22.55. The company has a market capitalization of $505.19 million, a price-to-earnings ratio of 10.77 and a beta of 0.86. The business’s fifty day simple moving average is $19.37 and its two-hundred day simple moving average is $17.01.

Hedge Funds Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in Keros Therapeutics by 3.3% during the third quarter. Vanguard Group Inc. now owns 2,718,777 shares of the company’s stock valued at $43,011,000 after buying an additional 87,129 shares during the period. Western Standard LLC boosted its stake in shares of Keros Therapeutics by 42.7% during the 3rd quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock worth $34,644,000 after acquiring an additional 654,989 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Keros Therapeutics by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 829,297 shares of the company’s stock valued at $11,073,000 after acquiring an additional 23,112 shares during the period. Jacobs Levy Equity Management Inc. grew its position in shares of Keros Therapeutics by 26.6% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 768,425 shares of the company’s stock valued at $15,645,000 after acquiring an additional 161,336 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in shares of Keros Therapeutics by 38.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after purchasing an additional 205,022 shares in the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.